Cargando…
Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multidisciplinary approach is essential to the success...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123678/ https://www.ncbi.nlm.nih.gov/pubmed/37092519 http://dx.doi.org/10.3390/hematolrep15020025 |
_version_ | 1785029708862193664 |
---|---|
author | Liu, Angela Vicenzi, Paige Sharma, Ishna Orr, Kaci Teller, Christa Koentz, Micha Trinkman, Heidi Vallance, Kelly Ray, Anish |
author_facet | Liu, Angela Vicenzi, Paige Sharma, Ishna Orr, Kaci Teller, Christa Koentz, Micha Trinkman, Heidi Vallance, Kelly Ray, Anish |
author_sort | Liu, Angela |
collection | PubMed |
description | The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multidisciplinary approach is essential to the success of MTBs. Our MTB, consisting of pediatric oncologists, pathologists, and pharmacists, evaluated 115 cases diagnosed between March 2016 and September 2021. If targetable mutations were identified, pharmacists aided in the evaluation of treatment options based on drug accessibility. Treatable genetic alterations detected through molecular testing most frequently involved the cell cycle. For 85% of the cases evaluated, our MTB provided treatment recommendations based on the patient’s history and results of molecular tumor testing. Only three patients, however, received MTB-recommended targeted therapy, and only one of these patients demonstrated an improved clinical outcome. For the remaining patients, MTB-recommended treatment often was not administered because molecular tumor profiling was not performed until late in the disease course. For the three patients who did receive MTB-recommended therapy, such treatment was not administered until months after diagnosis due to physician preference. Thus, the education of healthcare providers regarding the benefits of targeted therapy may increase acceptance of these novel agents and subsequently improve patient survival. |
format | Online Article Text |
id | pubmed-10123678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101236782023-04-25 Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care Liu, Angela Vicenzi, Paige Sharma, Ishna Orr, Kaci Teller, Christa Koentz, Micha Trinkman, Heidi Vallance, Kelly Ray, Anish Hematol Rep Article The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multidisciplinary approach is essential to the success of MTBs. Our MTB, consisting of pediatric oncologists, pathologists, and pharmacists, evaluated 115 cases diagnosed between March 2016 and September 2021. If targetable mutations were identified, pharmacists aided in the evaluation of treatment options based on drug accessibility. Treatable genetic alterations detected through molecular testing most frequently involved the cell cycle. For 85% of the cases evaluated, our MTB provided treatment recommendations based on the patient’s history and results of molecular tumor testing. Only three patients, however, received MTB-recommended targeted therapy, and only one of these patients demonstrated an improved clinical outcome. For the remaining patients, MTB-recommended treatment often was not administered because molecular tumor profiling was not performed until late in the disease course. For the three patients who did receive MTB-recommended therapy, such treatment was not administered until months after diagnosis due to physician preference. Thus, the education of healthcare providers regarding the benefits of targeted therapy may increase acceptance of these novel agents and subsequently improve patient survival. MDPI 2023-04-04 /pmc/articles/PMC10123678/ /pubmed/37092519 http://dx.doi.org/10.3390/hematolrep15020025 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Angela Vicenzi, Paige Sharma, Ishna Orr, Kaci Teller, Christa Koentz, Micha Trinkman, Heidi Vallance, Kelly Ray, Anish Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care |
title | Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care |
title_full | Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care |
title_fullStr | Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care |
title_full_unstemmed | Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care |
title_short | Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care |
title_sort | molecular tumor boards: the next step towards precision therapy in cancer care |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123678/ https://www.ncbi.nlm.nih.gov/pubmed/37092519 http://dx.doi.org/10.3390/hematolrep15020025 |
work_keys_str_mv | AT liuangela moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT vicenzipaige moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT sharmaishna moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT orrkaci moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT tellerchrista moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT koentzmicha moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT trinkmanheidi moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT vallancekelly moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare AT rayanish moleculartumorboardsthenextsteptowardsprecisiontherapyincancercare |